Osilodrostat Phosphate
Systematic Name
4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile dihydrogen phosphate
Osilodrostat Phosphate is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.
Therapeutic Category
Cortisol Synthesis Inhibitor
CAS No
104-31-41315449-72-9
Suitable Formulations
Solid
Approvals
Under Development